Answers are grounded in this paper and cite their sources.
Risankizumab demonstrated consistent and superior efficacy compared with ustekinumab regardless of patient demographics, disease characteristics or prior biologic exposure.
No takes yet. Share an insight, caveat, or question.
Strober et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: